Rapid Sublingual Absorption of Cyclobenzaprine (CBP) with Basifying Agents: Prospect for Bedtime Treatment of Fibromyalgia Syndrome (FM) Presentation Number: LB-026

Poster Presentation at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2016 Annual Meeting in San Diego, CA

Daugherty B, Monti NC, Panzeri V, Marelli R, Magnocavallo E, Reiner G, Lederman S. Rapid Sublingual Absorption of Cyclobenzaprine (CBP) with Basifying Agents: Prospect for Bedtime Treatment of Fibromyalgia Syndrome (FM). Poster session presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2016 Annual Meeting. 2016 Mar 8-12; San Diego, CA.

Comparative Neuropharmacology of Therapeutic Agents Targeting Posttraumatic Stress Disorder

Poster Presentaiton at the NEI Psychopharmacology Congress in November 2015.

Bruce L. Daugherty, Gregory M. Sullivan, Leland Gershell, Seth Lederman

An Evaluation of the Ef cacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) in Military-Related PTSD

Poster Presentation at the NEI Psychopharmacology Congress in November 2015.

Gregory M. Sullivan, Judy F. Gendreau, R. Michael Gendreau, Amy Schaberg, Bruce L. Daugherty, Heather Jividen, Ashild Peters, Perry Peters, Seth Lederman

Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study

Poster Presentation at the American College of Rheumatology (ACR) 2015 Annual Meeting in San Francisco, CA

Lederman S, Gendreau RM, Clauw DJ, Arnold LM, Gendreau J, Daugherty B, Forst A. Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study [abstract]. Arthritis Rheumatol. 2015; 67 (Suppl 10).

Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL)

Poster Presentation at the American College of Rheumatology (ACR) 2015 Annual Meeting in San Francisco, CA

Moldofsky H, Gendreau RM, Clauw DJ, Gendreau J, Vaughn B, Daugherty B, Forst A, Sullivan G, Lederman S. Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL) [abstract]. Arthritis Rheumatol. 2015; 67 (Suppl 10).

Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL)

Poster Presentation at the American College of Rheumatology (ACR) 2015 Annual Meeting in San Francisco, CA

Gendreau RM, Clauw DJ, Gendreau J, Daugherty B, Lederman S. Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) [abstract]. Arthritis Rheumatol. 2015; 67 (Suppl 10).

The AtEase Study: An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD

Poster Presentation at the Military Health System Research Symposium (MHSRS) 2015 Annual Meeting in Fort Lauderdale, FL

Sullivan GM, Gendreau JF, Gendreau RM, Schaberg A, Daugherty BL, Jividen H, Peters A, Peters P, Lederman S. The AtEase Study: An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD. Poster session presented at: 2015 Military Health System Research Symposium (MHSRS); 2015 Aug 17-21; Ft. Lauderdale, FL.

(R)-isometheptene* (IMH) Binds to the Imidazoline-1 Receptor and (S)-IMH increases Blood Pressure: Potentially Superior Benefit-to-Risk Ratio for (R)-IMH as an Analgesic for Headache

Poster Presentation at the American Headache Society (AHS) 2015 Annual Meeting in Washington, DC

Daugherty B, Gershell L, Lederman S. (R)-Isometheptene (IMH)* Binds to the Imidazole-1 Receptor and (S)-IMH Increases Blood Pressure: Potentially Superior Benefit to Risk Ratio for (R)-IMH as an Analgesic for Headache. Headache. 2015; 55: 172.

The (R)- isomer of isometheptene*, decreases trigeminal sensitivity in the Inflammatory Soup and Spontaneous Trigeminal Allodynia rat models

Poster Presentation at the American Headache Society (AHS) 2015 Annual Meeting in Washington, DC

Fried NT, Oshinsky ML, Daugherty BL, Lederman S, Elliott MB. The (R)-isomer of Isometheptene*, decreases Trigeminal Sensitivity in a Rat Model of Primary Headache. 2015; 55: 184.

TNX-102 SL* for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization

Poster Presentation at the European Union League Against Rheumatism (EULAR) 2015 Annual Meeting in Rome, IT

Lederman S, Clauw D, Gendreau JF, Arnold L, Moldofsky H, Mease P, Daugherty BL, Gendreau RM. THU0325 TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization. Ann Rheum Dis. 2015; 74(Suppl 2): 313.